Kite Pharma (KITE) versus Stemline Therapeutics (STML) Head to Head Review

Stemline Therapeutics (NASDAQ: STML) and Kite Pharma (NASDAQ:KITE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Insider and Institutional Ownership

49.0% of Stemline Therapeutics shares are owned by institutional investors. Comparatively, 87.7% of Kite Pharma shares are owned by institutional investors. 16.7% of Stemline Therapeutics shares are owned by insiders. Comparatively, 14.0% of Kite Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Stemline Therapeutics and Kite Pharma, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stemline Therapeutics 0 0 6 0 3.00
Kite Pharma 0 10 7 0 2.41

Stemline Therapeutics currently has a consensus target price of $33.40, suggesting a potential upside of 137.72%. Kite Pharma has a consensus target price of $93.20, suggesting a potential downside of 48.22%. Given Stemline Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Stemline Therapeutics is more favorable than Kite Pharma.


This table compares Stemline Therapeutics and Kite Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stemline Therapeutics -4,689.63% -75.50% -64.20%
Kite Pharma -1,092.54% -59.15% -48.12%

Earnings and Valuation

This table compares Stemline Therapeutics and Kite Pharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Stemline Therapeutics $1.04 million 341.66 -$38.30 million ($2.57) -5.47
Kite Pharma N/A N/A N/A ($6.90) -26.09

Kite Pharma has higher revenue, but lower earnings than Stemline Therapeutics. Kite Pharma is trading at a lower price-to-earnings ratio than Stemline Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

About Kite Pharma

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply